A device for the detection of at least two threshold levels of a marker of myocardial injury in a patient sample comprising: one sample application zone; one or more fluid flow paths formed by one or more lateral flow substrates, and in fluid communication with the one sample application zones; wherein the one or more fluid flow paths are formed by one or more bibulous, absorbent, and/or porous membranes, wherein at least one of the one or more fluid flow paths further comprises membranes or porous pads of various porosity to filter cells and/or debris, which are located in proximity to the one sample application zone, wherein the one or more fluid flow paths comprise a first marker capture zone and a second marker capture zone, wherein the first and second capture zones are in series on a single flow path or are in separate flow paths, and wherein the first capture zone is configured to detectably capture the marker when present in the sample at or above a first threshold level, and the second capture zone is configured to detectably capture the marker when present in the sample at or above a second threshold; a first binding member having an attached or bound detectable label capable of forming a capturable and detectable complex with the marker in the capture zones; and a second binding member capable of forming a capturable and detectable complex with the marker in the capture zones; wherein the second binding member is either immobilized as a continuous area formed by deposited second binding member along the capture zones or is capable of being immobilized during sample flow as a continuous area formed by deposited second binding member along the capture zones, the marker being detectable in the sample by formation of a capturable and detectable complex formed with the first binding member and the second binding member that are included in the device; wherein the marker is a cardiac troponin, wherein the at least two threshold levels of marker are determined by the length of detectable complex binding along the two marker capture zones on each of the one or more fluid flow paths, thereby extending the range of detection, wherein the marker is detected at a first threshold level in the patient sample and a second threshold level in the patient sample, wherein the first threshold level corresponds to 0.04 ng/ml and is indicative of presence of the marker in blood circulation, and wherein the second threshold level corresponds to 0.1 ng/ml of marker and is indicative of an acute cardiac event. one sample application zone; one or more fluid flow paths formed by one or more lateral flow substrates, and in fluid communication with the one sample application zones; wherein the one or more fluid flow paths are formed by one or more bibulous, absorbent, and/or porous membranes, wherein at least one of the one or more fluid flow paths further comprises membranes or porous pads of various porosity to filter cells and/or debris, which are located in proximity to the one sample application zone, wherein the one or more fluid flow paths comprise a first marker capture zone and a second marker capture zone, wherein the first and second capture zones are in series on a single flow path or are in separate flow paths, and wherein the first capture zone is configured to detectably capture the marker when present in the sample at or above a first threshold level, and the second capture zone is configured to detectably capture the marker when present in the sample at or above a second threshold; a first binding member having an attached or bound detectable label capable of forming a capturable and detectable complex with the marker in the capture zones; and a second binding member capable of forming a capturable and detectable complex with the marker in the capture zones; wherein the second binding member is either immobilized as a continuous area formed by deposited second binding member along the capture zones or is capable of being immobilized during sample flow as a continuous area formed by deposited second binding member along the capture zones, the marker being detectable in the sample by formation of a capturable and detectable complex formed with the first binding member and the second binding member that are included in the device; wherein the marker is a cardiac troponin, wherein the at least two threshold levels of marker are determined by the length of detectable complex binding along the two marker capture zones on each of the one or more fluid flow paths, thereby extending the range of detection, wherein the marker is detected at a first threshold level in the patient sample and a second threshold level in the patient sample, wherein the first threshold level corresponds to 0.04 ng/ml and is indicative of presence of the marker in blood circulation, and wherein the second threshold level corresponds to 0.1 ng/ml of marker and is indicative of an acute cardiac event.